An AAV vector is a small engineered virus particle used to carry a DNA cassette into cells. Reaching a cell, keeping the DNA and making useful protein are separate steps, and each needs its own evidence in the cells that matter.
Recombinant AAV replaces the viral coding sequence with a designed cassette and regulatory sequences. The protein shell (capsid) influences which cells the particle enters; the cassette decides what those cells could make. The DNA still has to reach the nucleus and act as a template before RNA and protein appear, and an AAV is a different virus from an adenovirus.
Where the DNA sits was measured in different systems. In sequential muscle biopsies taken 3 and 12 months after an intramuscular AAV vector expressing alpha-1 antitrypsin, most vector DNA was double-stranded circular episomes, and clones recovered from the biopsies were transcriptionally active (Schnepp and colleagues; abstract read, full text not retrievable). After partial hepatectomy in mice, extrachromosomal genomes were the main form behind liver expression and in most cases no more than about 10 per cent of stably transduced genomes had integrated, although one of three mice at a higher dose had 67 per cent integrated genomes (Nakai and colleagues). That shows the usual behaviour of the tested vectors in those tissues, not that integration never happens, and persistent DNA does not show an intact cassette, enough protein or a surviving functional cell: in the muscle study the episomal inverted terminal repeats ranged from fully intact to severely deleted, so counting vector DNA is a different measurement from showing a working cassette.
Immunity and capacity also limit what a lot can do. In a phase 1/2 study in seven people with severe haemophilia B, an AAV2 factor IX vector infused through the hepatic artery reached therapeutic levels at the highest dose but expression lasted about 8 weeks; the authors' further studies suggested that cell-mediated immunity against capsid antigens destroyed transduced hepatocytes (Manno and colleagues). Neutralising antibodies against the capsid are why re-dosing is hard: a review notes that systemic AAV dosing needs patient stratification by antibody level and that re-administration then becomes very difficult (Naso and colleagues), and a 2024 mouse study, which opens by noting that AAV typically induces long-lasting neutralising antibodies that prevent re-administration, found that transient B-cell depletion (anti-CD20 with anti-BAFF) before hepatic AAV8 delivery allowed effective re-administration (Rana and colleagues). Whether a given product can be given again is a product-specific question, and that mouse experiment does not establish a clinical re-dosing protocol. For packaging, the AAV2 genome is a single-stranded DNA of 4,675 nucleotides (Srivastava and colleagues) and the original self-complementary-vector experiment used an inverted repeat that could pair with itself, bypassing synthesis of the second strand (McCarty and colleagues, 2001). McCarty's later review describes the trade-off as losing half the coding capacity. Report the capsid, cassette configuration and length being measured with a capacity figure; a measured packaged-genome length and usable coding capacity answer different questions. In the study of plasmid-encoded vectors of 4.7 to 8.7 kb in AAV2, AAV5 and AAV8 capsids, packaged genomes never exceeded 5.2 kb; genomes from plasmids over 5 kb were heterogeneous and truncated at the 5' end, and reporter expression in cells at high multiplicity of infection was substantially lower than from genomes under 5 kb (Wu and colleagues). FDA follow-up guidance says vectors such as AAV that do not tend to integrate or reactivate generally carry a lower risk of delayed adverse events, while product-specific modifications may change that, so safety is assessed per product.
AAV also appears in cell-engineering workflows without being the lasting product. In primary human T cells in culture, Cas9 mRNA and guide RNA were electroporated and a recombinant AAV6 vector added 2 to 4 hours later supplied a repair template encoding a CD19 CAR, which was knocked into the TRAC locus; the edited cells outperformed conventionally generated CAR T cells in a mouse leukaemia model (Eyquem and colleagues). There the AAV carried a donor template into cells outside the body and the lasting change was the knocked-in receptor, so an AAV in a workflow does not show direct targeting of T cells in a patient. Capsid variants differ in tissue tropism, for example AAV8 for liver in rodents and non-human primates (Naso and colleagues).
Muscle and liver observations, T-cell editing in culture and mouse leukaemia experiments answer different questions. Muscle or liver persistence does not establish how another cassette behaves in dividing T cells. A capsid that favours a tissue is a delivery feature, separate from what the encoded protein recognises; the cited experiments do not establish benefit for people with cancer.
Showing the technology this term belongs to: Viral vector manufacturing (lentiviral, retroviral, AAV).
Shares In vivo CAR-T and the tag delivery-vehicle.
Shares In vivo CAR-T and the tag delivery-vehicle.
Shares Lentiviral vector, Transposon systems for cell engineering, Viral vector manufacturing (lentiviral, retroviral, AAV).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/